EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Six-Gene Signature for Differential Diagnosis and Therapeutic Decisions in Non-Small-Cell Lung Cancer—A Validation Study

Radoslaw Charkiewicz iD, Anetta Sulewska iD, Piotr Karabowicz, Grzegorz Lapuc, Alicja Charkiewicz, Marcin Kraska, Joanna Pancewicz iD, Malgorzata Lukasik, Miroslaw Kozlowski, Rafal Stec, Dominika Ziembicka, Weronika Piszcz und 2 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25073607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Radoslaw Charkiewicz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center of Experimental Medicine, Medical University of Bialystok, 15-369 Bialystok, Poland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adenocarcinoma, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Centre for Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small-cell lung cancer (NSCLC) poses a challenge due to its heterogeneity, necessitating precise histopathological subtyping and prognostication for optimal treatment decision-making. Molecular markers emerge as a potential solution, overcoming the limitations of conventional methods and supporting the diagnostic–therapeutic interventions. In this study, we validated the expression of six genes (MIR205HG, KRT5, KRT6A, KRT6C, SERPINB5, and DSG3), previously identified within a 53-gene signature developed by our team, utilizing gene expression microarray technology. Real-time PCR on 140 thoroughly characterized early-stage NSCLC samples revealed substantial upregulation of all six genes in squamous cell carcinoma (SCC) compared to adenocarcinoma (ADC), regardless of clinical factors. The decision boundaries of the logistic regression model demonstrated effective separation of the relative expression levels between SCC and ADC for most genes, excluding KRT6C. Logistic regression and gradient boosting decision tree classifiers, incorporating all six validated genes, exhibited notable performance (AUC: 0.8930 and 0.8909, respectively) in distinguishing NSCLC subtypes. Nevertheless, our investigation revealed that the gene expression profiles failed to yield predictive value regarding the progression of early-stage NSCLC. Our molecular diagnostic models manifest the potential for an exhaustive molecular characterization of NSCLC, subsequently informing personalized treatment decisions and elevating the standards of clinical management and prognosis for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdenocarcinomaCarcinoma, Squamous CellSmall Cell Lung CarcinomaHumansDiagnosis, Differential

Stichwörter der Autor:innen

ADCNSCLC subtypingSCCgene expressionpersonalized medicineprognosisqPCRvalidation study

Autor:innen und Institutionen

  • Center of Experimental Medicine, Medical University of Bialystok, 15-369 Bialystok, Poland.
  • Department of Clinical Molecular Biology, Medical University of Bialystok, 15-269 Bialystok, Poland.
  • Biobank, Medical University of Bialystok, 15-269 Bialystok, Poland.
  • Department of Thoracic Surgery, Medical University of Bialystok, 15-269 Bialystok, Poland.
  • Department of Analysis and Bioanalysis of Medicines, Medical University of Bialystok, 15-089 Bialystok, Poland.
  • Department of Medical Pathomorphology, Medical University of Bialystok, 15-269 Bialystok, Poland.

ORCID-Profile: Radoslaw Charkiewicz, Anetta Sulewska, Joanna Pancewicz, Wojciech Miltyk

Förderung

  • National Centre for Research and Development

Zitieren

APA

Charkiewicz, R., Sulewska, A., Karabowicz, P., Lapuc, G., Charkiewicz, A., Kraska, M., Pancewicz, J., Lukasik, M., Kozlowski, M., Stec, R., Ziembicka, D., Piszcz, W., Miltyk, W., & Niklinska, W. (2024). Six-Gene Signature for Differential Diagnosis and Therapeutic Decisions in Non-Small-Cell Lung Cancer—A Validation Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25073607

Vancouver

Charkiewicz R, Sulewska A, Karabowicz P, Lapuc G, Charkiewicz A, Kraska M, et al. Six-Gene Signature for Differential Diagnosis and Therapeutic Decisions in Non-Small-Cell Lung Cancer—A Validation Study. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25073607

BibTeX
@article{Charkiewicz2024,
  author = {Charkiewicz, Radoslaw and Sulewska, Anetta and Karabowicz, Piotr and Lapuc, Grzegorz and Charkiewicz, Alicja and Kraska, Marcin and Pancewicz, Joanna and Lukasik, Malgorzata and Kozlowski, Miroslaw and Stec, Rafal and Ziembicka, Dominika and Piszcz, Weronika and Miltyk, Wojciech and Niklinska, Wieslawa},
  title = {Six-Gene Signature for Differential Diagnosis and Therapeutic Decisions in Non-Small-Cell Lung Cancer—A Validation Study},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25073607}
}
Kostenlos starten →